Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study.
Journal: RMD open
Published: August 08, 2024
A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment.
Journal: Rheumatology (Oxford, England)
Published: April 17, 2024
Hearing Loss As A Surrogate Marker For Early Atherosclerosis in A High-Risk Population: A Prospective Study.
Journal: The American journal of cardiology
Published: August 25, 2023
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis.
Journal: The New England journal of medicine
Published: May 17, 2023
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: November 15, 2022
Preventive care: vaccines matter.
Journal: The American journal of managed care
Published: July 27, 2021
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.
Journal: The Journal of rheumatology
Published: January 14, 2021
FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.
Journal: Arthritis research & therapy
Published: April 05, 2019
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study.
Journal: Rheumatology and therapy
Published: April 03, 2019
Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.
Journal: Rheumatology and therapy
Published: February 09, 2018
Last Updated: 09/26/2026